{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:00:30Z","timestamp":1793678430438,"version":"4.5.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PSI - Paul Scherrer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate why small- and certain medium-sized parapapillary choroidal melanoma (pcM) patients treated with hypo-fractionated proton therapy (PT) retain excellent long-term visual acuity (VA) and assess the negative predictive factors for retaining good vision (\u2264\u20090.2 logMAR (\u2265\u20090.6 decimal) after 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center, retrospective, comparative study recruited consecutive pcM patients that were treated with PT. Between 1984 and 2005, 609 patients received a total of 60 CGE, of whom 310 met the following inclusion criteria: posterior tumor border\u2009\u2264\u20092.5\u00a0mm from the optic disc, largest tumor diameter\u2009\u2264\u200917.9\u00a0mm, tumor thickness\u2009\u2264\u20095.2\u00a0mm and available follow-up data for at least 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean follow-up was 120.8\u2009\u00b1\u200948.8\u00a0months (54.0\u2013295.0). Out of 310 patients, 64 (21%) maintained a VA\u2009\u2264\u20090.2 logMAR (\u2265\u20090.6 decimal) for at least 5\u00a0years following PT and were allocated to the \u201cgood visual outcome\u201d (GVO) group, while the remaining 246 (79%) constituted the \u201cpoor visual outcome\u201d (PVO) group, subdivided into 70 (22%) with a VA of 0.3\u20131.0 logMAR (0.1\u20130.5 decimal) and 157 (57%) patients with a VA\u2009&gt;\u20091.0 logMAR (&lt;\u20090.1 decimal). On multivariate analysis, older age (<jats:italic>P<\/jats:italic>\u2009=\u20090.04), tumor localization\u2009\u2264\u20090.5\u00a0mm to the fovea (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.03), volume of the optic disc and macula receiving 50% of dose (30 CGE) (<jats:italic>P<\/jats:italic>\u2009=\u20090.02 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, respectively) were independent negative predictors of GVO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Of 310 small- to medium-sized pcM patients successfully treated with PT, 21% retained a VA\u2009\u2264\u20090.2 logMAR (\u2265\u20090.6 decimal) for at least 5\u00a0years. Strongest negative predictive factor for retaining good long-term vision was the volume of the macula irradiated with at least 30\u00a0Gy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10792-020-01594-z","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T10:03:47Z","timestamp":1601028227000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-8654","authenticated-orcid":false,"given":"Alessia","family":"Pica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureen","family":"Vallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hrbacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Schalenbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"1594_CR1","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 124(12):1684\u20131693","DOI":"10.1001\/archopht.124.12.1684"},{"issue":"8","key":"1594_CR2","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0161-6420(99)90455-4","volume":"106","author":"ES Gragoudas","year":"1999","unstructured":"Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM (1999) Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106(8):1571\u20131577 (discussion 1577\u20131578)","journal-title":"Ophthalmology"},{"issue":"4","key":"1594_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0360-3016(02)04200-1","volume":"55","author":"E Egger","year":"2003","unstructured":"Egger E, Zografos L, Schalenbourg A, Donata B, B\u00f6hringer T, Chamot L, Goitein G (2003) Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 55(4):867\u2013880","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1594_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/archophthalmol.2011.228","volume":"129","author":"AM Lane","year":"2011","unstructured":"Lane AM, Kim IK, Gragoudas ES (2011) Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol 129(9):1127\u20131130","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1594_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ajo.2014.02.032","volume":"157","author":"AI Riechardt","year":"2014","unstructured":"Riechardt AI, Cordini D, Willerding GD, Georgieva I, Weber A, Seibel I, Lakotka N, Bechrakis NE, Foerster MH, Moser L, Joussen AM (2014) Proton beam therapy of parapapillary choroidal melanoma. Am J Ophthalmol 157(6):1258\u20131265","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1594_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijrobp.2015.12.011","volume":"95","author":"J Thariat","year":"2016","unstructured":"Thariat J, Grange JD, Mosci C, Rosier L, Maschi C, Lanza F, Nguyen AM, Jaspart F, Bacin F, Bonnin N, Gaucher D, Sauerwein W, Angellier G, H\u00e9rault J, Caujolle JP (2016) Visual outcomes of parapapillary uveal melanomas following proton beam therapy. Int J Radiat Oncol Biol Phys 95(1):328\u2013333","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1594_CR7","first-page":"805","volume-title":"The AJCC Cancer Staging Manual","author":"T Kivela","year":"2017","unstructured":"Kivela T, Simpson RE, Grossniklaus HE, Jager MJ, Singh AD, Caminal JM, Pavlick AC, Kujala E, Coupland SE (2017) Finger PT (2017) Uveal melanoma. In: Amin MB, Edge SB, Greene FL, et al. (eds) The AJCC cancer staging manual, 8th edn. Springer, New York, NY, pp 805\u2013818","edition":"8"},{"issue":"Suppl 2","key":"1594_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/BF03038879","volume":"175","author":"E Pedroni","year":"1999","unstructured":"Pedroni E, B\u00f6hringer T, Coray A, Egger E, Grossmann M, Lin S, Lomax A, Goitein G, Roser W, Schaffner B (1999) Initial experience of using an active beam delivery technique at PSI. Strahlenther Onkol 175(Suppl 2):18\u201320","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"1594_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0161-6420(80)35212-3","volume":"87","author":"ES Gragoudas","year":"1980","unstructured":"Gragoudas ES, Goitein M, Verhey L, Munzenreider J, Suit HD, Koehler A (1980) Proton beam irradiation An alternative to enucleation for intraocular melanomas. Ophthalmology 87(6):571\u2013581","journal-title":"Ophthalmology"},{"issue":"1","key":"1594_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0360-3016(01)01560-7","volume":"51","author":"E Egger","year":"2001","unstructured":"Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, Goitein G (2001) Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 51(1):138\u2013147","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1594_CR11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","volume":"13","author":"JT Holladay","year":"1997","unstructured":"Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13(4):388\u2013391","journal-title":"J Refract Surg"},{"issue":"1","key":"1594_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M (2009) Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 247(1):137\u2013142","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1594_CR13","unstructured":"R software package 2.15.1 R (Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"issue":"8","key":"1594_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ophtha.2009.12.015","volume":"117","author":"IK Kim","year":"2010","unstructured":"Kim IK, Lane AM, Egan KM, Munzenrider J, Gragoudas ES (2010) Natural history of radiation papillopathy after proton beam irradiation of parapapillary melanoma. Ophthalmology 117(8):1617\u20131622","journal-title":"Ophthalmology"},{"issue":"Pt 1","key":"1594_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/eye.1990.3","volume":"4","author":"JM Olver","year":"1990","unstructured":"Olver JM, Spalton DJ, McCartney AC (1990) Microvascular study of the retrolaminar optic nerve in man: the possible significance in anterior ischaemic optic neuropathy. Eye (Lond) 4(Pt 1):7\u201324","journal-title":"Eye (Lond)"},{"issue":"10","key":"1594_CR16","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1167\/iovs.17-22324","volume":"58","author":"A Matet","year":"2017","unstructured":"Matet A, Daruich A, Zografos L (2017) Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity. Invest Ophthalmol Vis Sci 58(10):3851\u20133861","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1594_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04780-y","author":"AI Riechardt","year":"2020","unstructured":"Riechardt AI, Stroux A, Seibel I, Heufelder J, Zeitz O, B\u00f6hmer D, Joussen AM, Gollrad J (2020) Side effects of proton beam therapy of choroidal melanoma in dependence of the dose to the optic disc and the irradiated length of the optic nerve. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-020-04780-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01594-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T01:16:33Z","timestamp":1632532593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01594-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01594-z","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The responsible ethics committee (the ethics commission of Vaud canton, Prot.: 2016\u201301861) approved this study and waived written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}